The PTH (1-84)/non-PTH (1-84) ratio is a risk factor for cardiovascular events in hemodialysis patients

被引:8
作者
Zitt, E. [2 ,3 ]
Kirsch, A. H.
Haueis, M.
Strasak, A. [4 ]
Neyer, U. [2 ,3 ]
Mayer, G.
Rosenkranz, A. R. [1 ]
机构
[1] Med Univ Innsbruck, Univ Klin Innere Med 4, Dept Internal Med 4, A-6020 Innsbruck, Austria
[2] Acad Teaching Hosp Feldkirch, Dept Nephrol & Dialysis, Feldkirch, Austria
[3] VIVIT, Feldkirch, Austria
[4] Med Univ Innsbruck, Dept Med Stat, A-6020 Innsbruck, Austria
关键词
PTH; secondary hyperparathyroidism; PTH (1-84)/non-PTH (1-84) ratio; cardiovascular morbidity; cardiovascular mortality; hemodialysis; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; PARATHYROID-HORMONE ASSAYS; INCIDENT DIALYSIS PATIENTS; ALL-CAUSE MORTALITY; VASCULAR CALCIFICATION; BONE HISTOMORPHOMETRY; MINERAL METABOLISM; SERUM-CALCIUM; ASSOCIATION;
D O I
10.5414/CNP75309
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: We hypothesized that the PTH (1-84)/non-PTH (1-84) ratio (PTH ratio) might help to assess cardiovascular risk in hemodialysis patients. Methods: In this prospective cohort study 70 prevalent hemodialysis patients were followed up to 4 years. The PTH ratio was determined at base-line. Primary outcomes were cardiovascular events (CV E) and all-cause mortality. Cumulative event-free survival was compared between patients with a ratio < 1 and those with a ratio > 1. The risk-association of the PTH ratio with CVE was examined using an adjusted Multiple Cox Proportional Hazards model. Results: A PTH ratio > 1 was found in 34 patients (49%). During follow-up 26 patients suffered a CVE. Patients with a CVE showed a higher ratio than patients with event-free survival (p = 0.033). In patients with a ratio > 1 a significantly higher number of CVE occurred (53 vs. 22%; p = 0.013), and these patients showed a significantly shorter event-free survival (p = 0.032). In an adjusted Cox-proportional hazards model a higher PTH ratio was found to be independently associated with an elevated risk for CVE (HR = 3.2; 95% Cl 1.06 - 13.63; p = 0.04). Conclusions: A higher PTH (1-84)/non-PTH (1-84) ratio is associated with an increased risk for CVE in hemodialysis patients and might therefore be useful for cardiovascular risk estimation in this population.
引用
收藏
页码:309 / 318
页数:10
相关论文
共 50 条
  • [41] REPLACEMENT THERAPY WITH RECOMBINANT PARATHYROID HORMONE (1-84) IN HYPOPARATHYROIDISM
    Galoiu, S.
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2015, 11 (03) : 413 - 414
  • [42] Comparison of 1-84 and intact parathyroid hormone assay in pediatric dialysis patients
    Rita D. Sheth
    Stuart L.Goldstein
    Pediatric Nephrology, 2005, 20 : 977 - 981
  • [43] Comparison of 1-84 and intact parathyroid hormone assay in pediatric dialysis patients
    Sheth, RD
    Goldstein, SL
    PEDIATRIC NEPHROLOGY, 2005, 20 (07) : 977 - 981
  • [44] Direct comparison between two 1-84PTH assays in dialysis patients
    Kazama, JJ
    Yamamoto, S
    Kameda, S
    Maruyama, H
    Narita, I
    Shigematsu, T
    Gejyo, F
    NEPHRON CLINICAL PRACTICE, 2005, 99 (01): : C8 - C12
  • [45] Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine
    Fox, John
    Miller, Michael A.
    Newman, Michael K.
    Turner, Charles H.
    Recker, Robert R.
    Smith, Susan Y.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (02) : 260 - 273
  • [46] Mechanisms of vasodilation to PTH 1–84, PTH 1–34, and PTHrP 1–34 in rat bone resistance arteries
    T. Benson
    T. Menezes
    J. Campbell
    A. Bice
    B. Hood
    R. Prisby
    Osteoporosis International, 2016, 27 : 1817 - 1826
  • [47] Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients
    Chudek, J
    Piecha, G
    Kokot, F
    Wiecek, A
    JOURNAL OF NEPHROLOGY, 2003, 16 (05) : 710 - 715
  • [48] Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: An 18-month open-labeled observational study using HR-pQCT
    Hansen, Stinus
    Hauge, Ellen M.
    Jensen, Jens-Erik Beck
    Brixen, Kim
    JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (04) : 736 - 745
  • [49] The risk of chronic kidney disease development in adult patients with chronic hypoparathyroidism treated with rhPTH(1-84): A retrospective cohort study
    Rejnmark, Lars
    Ayodele, Olulade
    Lax, Angela
    Mu, Fan
    Swallow, Elyse
    Gosmanova, Elvira O.
    CLINICAL ENDOCRINOLOGY, 2023, 98 (04) : 496 - 504
  • [50] Using parathyroid hormone 1-84 in the treatment of osteoporosis: presentation and comments of main clinical trial
    Cesareo, R.
    Napolitano, C.
    Iozzino, A.
    Romitelli, F.
    Iarussi, G.
    Scona, M.
    De Rosa, B.
    CLINICA TERAPEUTICA, 2009, 160 (04): : 307 - 310